Cano MM, Calonge ML, Ilundain AA
The practical takeaway is straightforward
Here, I review this remarkable development from the earliest observations of glucose lowering and modest weight losses with native glucagon-like peptide (GLP)-1 and short acting compounds, to the recent development of highly active formulations and new molecules
To learn more about this report, GLP-1 Receptor Agonist Market Insights, By Route of Administration: Parenteral Contributes the Highest Share of the Market Due to its Convenience By route of administration, the parenteral segment is estimated to contribute the highest market share owing to its unparalleled convenience
An independent pharmacy fills and ships the prescription
In this Review, we summarize current preclinical and clinical evidence, showing that the riskbenefit profile of GLP1RAs remains favourable in individuals with T2DM and obesity, although caution is warranted in those with a low cardiometabolic risk, for whom the potential risks of cancer might outweigh any expected benefits